Table 7.
The comparison of treatment in hospital between PE and non-PE patients with COVID-19.
| Treatment | Sample size | Pooled results | Analytic effect model | ||
|---|---|---|---|---|---|
| OR | 95% CI | P value | |||
| Azithromycin | 30 | 0.22 | 0.04, 1.11 | 0.07 | Fixed effect model |
| Hydroxychloroquine | 30 | 2.15 | 0.17, 26.67 | 0.55 | Fixed effect model |
| Lopinavir + Ritonavir | 30 | 0.76 | 0.18, 3.24 | 0.71 | Fixed effect model |
| Tocilizumab | 30 | 0.42 | 0.09, 1.92 | 0.26 | Fixed effect model |
| Other biological therapy | 30 | 3.21 | 0.12, 85.20 | 0.49 | Fixed effect model |
| Systemic corticosteroids | 55 | 1.03 | 0.33, 3.25 | 0.95 | Fixed effect model |
COVID-19 = coronavirus disease 2019, OR = odds ratio, PE = pulmonary embolism.